Stephanie Bohannon, APRN
Psychiatric/Mental Health · Fayetteville, ARNPI 1104459114
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Axsome Therapeutics, Inc. accounts for 68.4% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $16,295, 9.5 times the $1,707 reported in 2021. Among psychiatric/mental health clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 553 payments — averaging $58.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$22K
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Corium, LLC$797
- Vanda Pharmaceuticals Inc.$711
- Neurocrine Biosciences, Inc.$556
- plus $4K from 17 others
What the payments were for
- Consulting fees$7,50023%
- Speaking & faculty fees$13,25041%
- Travel & lodging$1,2914%
- Food & beverage$10,33232%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 53 | $22,153 |
| AbbVie | 90 | $3,083 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 97 | $1,332 |
| Corium, LLC | 45 | $797 |
| Vanda Pharmaceuticals Inc. | 36 | $711 |
| Neurocrine Biosciences, Inc. | 25 | $556 |
| Johnson & Johnson | 21 | $487 |
| Supernus Pharmaceuticals, Inc. | 29 | $482 |
| Otsuka America Pharmaceutical, Inc. | 24 | $457 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $340 |
| Alkermes, Inc. | 18 | $321 |
| Sunovion Pharmaceuticals Inc. | 16 | $314 |
| Eisai Inc. | 21 | $309 |
| Lundbeck LLC | 16 | $256 |
| Teva Pharmaceuticals USA, Inc. | 12 | $243 |
| Neuronetics, Inc. | 4 | $188 |
| Indivior Inc. | 5 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Merck | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,381 in reported general payments places this provider in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 14 | $18,885 |
| VraylarCariprazine Hcl | 13 | $18,820 |
| TrintellixVortioxetine Hydrobromide | 15 | $11,443 |
| Duloxetine Hcl | 54 | $1,155 |
| Aripiprazole | 18 | $964 |
| Lurasidone Hcl | 18 | $912 |
| Oxcarbazepine | 20 | $809 |
| Bupropion XlBupropion Hcl | 26 | $468 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $422 |
| Hydroxyzine Hcl | 17 | $268 |
| Mirtazapine | 14 | $241 |
| Doxazosin Mesylate | 16 | $218 |
| Buspirone Hcl | 20 | $214 |
| Trazodone Hcl | 40 | $212 |
| Lamotrigine | 22 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $487 | $18,88514 claims |
| AbbVieVraylar | $3,083 | $18,82013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $340 | $11,44315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Fayetteville
- Jennifer PenneFayetteville$11K
- Ashlea BrewerFayetteville$7K
- Jessica MusgroveFayetteville$7K
- Sarah WeatherfordFayetteville$5K
- Kelly McCartyFayetteville$4K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
- Mallori LevengoodPine Bluff$11K
- Stephanie ParishSearcy$9K
- Elizabeth HardyTexarkana$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.